RedHill Biopharma Announces FDA Orphan Drug Designation for RHB-204 for the Treatment of NTM Infections

TEL AVIV, Israel and RALEIGH, NC, October 14, 2020, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to

New tricks for old antibiotics

Sepsis is estimated to cause 11 million deaths every year around the world. Its treatment is based on the use of antibiotics and organ support measures, but many times it fails due to unsuccessful attempts